Laboratorios Farmaceuticos Rovi, S.A.

LABORATORIOS FARMACEUTICOS ROVI SA's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, LABORATORIOS FARMACEUTICOS ROVI SA has 51.14M shares outstanding.

As of June 30, 2026, LABORATORIOS FARMACEUTICOS ROVI SA maintains a current ratio of 2.05, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.02, indicating elevated leverage, while an interest coverage ratio of 68.05 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, LABORATORIOS FARMACEUTICOS ROVI SA posted a return on equity (ROE) of 29.30, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 23.99 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 18.55, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 24.66, useful for judging operating efficiency across full business cycles. The company generates approximately 397,250.12 in revenue per employee across its workforce of 2,223.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.87 indicates how many times LABORATORIOS FARMACEUTICOS ROVI SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, LABORATORIOS FARMACEUTICOS ROVI SA recorded 57.31M in income tax expense. That works out to an effective tax rate of 21.33, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 268.72M, leaving 211.56M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on August 3, 2026, LABORATORIOS FARMACEUTICOS ROVI SA's stock has gained approximately 1.98% over the past 52 weeks.

Over the twelve months ended June 30, 2026, LABORATORIOS FARMACEUTICOS ROVI SA generated 883.19M in revenue and converted that into 211.56M in net income, yielding earnings per share of 4.13. EBITDA reached 310.26M, while operating income came in at 200.64M.

As of June 30, 2026, LABORATORIOS FARMACEUTICOS ROVI SA holds 146.32M in cash and equivalents against 123.03M in total debt, resulting in a net debt position of -145.06M. Total book value stands at 800.43M, with working capital of 332.93M providing operational flexibility.

LABORATORIOS FARMACEUTICOS ROVI SA produced 289.40M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -88.42M in capital expenditures, free cash flow totaled 200.98M - equivalent to 3.93 per share.

Over the twelve months ended June 30, 2026, LABORATORIOS FARMACEUTICOS ROVI SA posted a gross margin of 66.17, reflecting its pricing power and cost economics. The operating margin of 22.72 and net profit margin of 23.95 provide insight into operational efficiency.